Get the Stockscreener App
1.66
0.60%
-0.01
After Hours:
1.71
0.05
+3.01%
Aprea Therapeutics Inc stock is traded at $1.66, with a volume of 93,479.
It is down -0.60% in the last 24 hours and down -6.09% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.67
Open:
$1.71
24h Volume:
93,479
Relative Volume:
2.49
Market Cap:
$9.18M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.416
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-4.05%
1M Performance:
-6.09%
6M Performance:
-56.87%
1Y Performance:
-58.50%
1-Day Range:
$1.63
$1.75
1-Week Range:
$1.61
$1.78
52-Week Range:
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.66 | 9.57M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea Therapeutics Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - PrintWeekIndia
What analysts say about Aprea Therapeutics Inc. stockExplosive trading opportunities - PrintWeekIndia
Is Aprea Therapeutics Inc. a good long term investmentFree Capital Efficiency Planning - Autocar Professional
What drives Aprea Therapeutics Inc. stock priceHigh-yield portfolio picks - Autocar Professional
Franklin Covey Co. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
What analysts say about AMBO stockExplosive earning power - Jammu Links News
Why Aprea Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Courses - Newser
What makes Aprea Therapeutics Inc. stock price move sharplyFree Access to Investment Community - Newser
How Rocky Mountain Chocolate Factory Inc. stock performs during market volatilityFree Consultation - Newser
How Aprea Therapeutics Inc. stock performs during market volatilityConsistent High Return Strategy - Newser
Aprea Therapeutics Insiders Still US$86k Away From Original Investment Value - simplywall.st
Aprea Therapeutics (NASDAQ:APRE) Trading 4.4% Higher – What’s Next? - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MSN
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers - MyChesCo
Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News - GuruFocus
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - Morningstar
Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
CoreWeave Stock Skyrockets 137% In A Month: Hold Or Fold? - Barchart.com
Block Inc. Has Unusual Put Option ActivityShowing Bullish XYZ Investors - Barchart.com
Ostara Inc. Launches CG P2X In Western Canada: Phosphorus, Perfected - Barchart.com
Stocks In Play: WSP Global Inc. - Barchart.com
Alzheimer’s Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Dry Eye Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - Barchart.com
Supporting 2SLGBTQI+ Communities For A Safer, More Equitable And Inclusive Canada - Barchart.com
Artios' AACR Data Success: What It Means For Aprea Therapeutics' ATRN-119 Program - Barchart.com
REKO INTERNATIONAL GROUP INC. TO BUY BACK UP TO 276,066 OF ITS COMMON SHARES - Barchart.com
Aprea Therapeutics Confirms Directors and Accounting Firm - TipRanks
Stocks Finish Sharply Higher On A Resilient US Labor Market - Barchart.com
Compass Refresh, Inc. Launches New Headquarters in Sulphur Springs, TX – Bringing High-Quality Exterior Maintenance Across the Southern Region - Barchart.com
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Stocks In Play: Aimia Inc. - Barchart.com
ADF GROUP INC. Q1-2026 CONFERENCE CALL INVITATION - Barchart.com
BNP Paribas Financial Markets Takes $43,000 Position in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
Galaxy Digital Inc. Announces Public Offering Of Common Stock - Barchart.com
Vermilion Energy Inc. Advances Strategic Portfolio Repositioning with Agreement to Sell its Saskatchewan Assets and Accelerate Debt Repayment - Barchart.com
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Ovarian Cancer Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Q2 Earnings Estimate for APRE Issued By Wedbush - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Earns “Buy” Rating from B. Riley - Defense World
The Manufacturers Life Insurance Company Sells 752 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) - Defense World
The Manufacturers Life Insurance Company Purchases 993 Shares of CTO Realty Growth, Inc. (NYSE:CTO) - Defense World
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):